- Home
- CHEC vs MBOT Comparison
CHEC vs MBOT Comparison
Compare CHEC & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.47
Company Overview
Basic Information| Metric | CHEC | MBOT |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 145.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CHEC | MBOT |
|---|---|---|
| Price | $10.05 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 128.8K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,186.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.91 | $1.34 |
| 52 Week High | $10.56 | $4.62 |
Technical Indicators
Market Signals| Indicator | CHEC | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 60.71 |
| Support Level | $10.02 | $2.34 |
| Resistance Level | $10.56 | $2.68 |
| Average True Range (ATR) | 0.00 | 0.20 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 60.40 | 67.61 |
Price Performance
Historical Comparison CHEC
MBOT
About CHEC Chenghe Acquisition III Co. Class A Ordinary Share
Chenghe Acquisition III Co is blank check company.
About MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.